2. Signaling Pathways
  3. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
  4. EGFR
  5. ErbB2/HER2 Isoform

ErbB2/HER2

 
Cat. No. Product Name Effect Purity
  • HY-P9907
    Trastuzumab
    		Inhibitor 99.80%
    Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2.
  • HY-10261
    Afatinib
    		Inhibitor 99.93%
    Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.
  • HY-50898
    Lapatinib
    		Inhibitor 99.83%
    Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
  • HY-32721
    Neratinib
    		Inhibitor 99.59%
    Neratinib (HKI-272) is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively.
  • HY-16069
    Tucatinib
    		Inhibitor 99.82%
    Tucatinib (Irbinitinib) is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM.
  • HY-153110A
    Larotinib mesylate hydrate
    		Inhibitor
    Larotinib mesylate hydrate is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC50 of 0.6 nM.
  • HY-P99380
    Zanidatamab
    		Inhibitor
    Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4).
  • HY-P99630
    Gancotamab
    		Inhibitor
    Gancotamab (MM-302) is a HER2-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity.
  • HY-135815
    Mobocertinib
    		Inhibitor 99.60%
    Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor.
  • HY-13272
    Dacomitinib
    		Inhibitor 99.74%
    Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively.
  • HY-P9912
    Pertuzumab
    		Inhibitor 99.10%
    Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
  • HY-13050
    Sapitinib
    		Inhibitor 99.93%
    Sapitinib (AZD-8931) is a reversible, ATP competitive EGFR inhibitor of with IC50s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively.
  • HY-104065
    Pyrotinib
    		Inhibitor 99.80%
    Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively.
  • HY-13501
    Mubritinib
    		Inhibitor 99.91%
    Mubritinib (TAK-165) is a potent and selective EGFR2/HER2 inhibitor with an IC50 of 6 nM.
  • HY-136789
    Tuxobertinib
    		Inhibitor 99.94%
    Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants.
  • HY-10223
    CUDC-101
    		Inhibitor 99.19%
    CUDC-101 is a potent inhibitor of HDAC, EGFR, and HER2 with IC50s of 4.4, 2.4, and 15.7 nM, respectively.
  • HY-P9985
    Disitamab vedotin
    		Inhibitor
    Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE).
  • HY-10367
    Canertinib
    		Inhibitor 99.95%
    Canertinib (CI-1033;PD-183805) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM.
  • HY-10261A
    Afatinib dimaleate
    		Inhibitor 99.88%
    Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.
  • HY-10530
    Varlitinib
    		Inhibitor 98.03%
    Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.
Cat. No. Product Name / Synonyms Species Source